Quadrature Capital’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Quadrature Capital's RAPP Position: Q3 2026 in Review
Quadrature Capital increased its Rapport Therapeutics (RAPP) stake by 345% in Q3 2026, buying an estimated $948K and bringing the position to 28,318 shares worth $951K. The position accounts for 0.01% of the portfolio, ranked #1074.
Quadrature Capital first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 167 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Quadrature Capital held 28,318 shares of Rapport Therapeutics worth $951K as of Q3 2026.
- Quadrature Capital bought 21,959 Rapport Therapeutics shares in Q3 2026, an estimated $948K.
- Rapport Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q3 2026, its #1074 holding.
- Quadrature Capital first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
- 167 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Quadrature Capital's 13F filing for Q3 2026, filed 13 Nov 2026.